The company, founded in 2019 and headquartered in Canada, is dedicated to creating safe and effective therapeutics for mental health issues by working with world-class partners and scientists. Cybin's focus is on progressing Psychedelics to Therapeutics™ by developing proprietary drug discovery platforms, innovative drug delivery systems, and treatment regimens for mental health disorders. With operations in Canada, the United States, United Kingdom, and Ireland, Cybin is leading the way in ethical biopharmaceuticals.